

PFKFB3 is a critical regulator of neutrophil metabolism and function in rheumatoid arthritis

Michele Fresneda Alarcon¹, Genna Ali Abdullah¹, Andrew Nolan¹, Christina Linford¹, Marie M Phelan^{2,3}, Helen L Wright¹

¹Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, L7 8TX, UK

²Institute of Systems Molecular and Integrative Biology, University of Liverpool, Liverpool, L69 7BE, UK

³High Field NMR Facility, Liverpool Shared Research Facilities University of Liverpool, Liverpool, L69 7TX, UK

Correspondence: Dr Helen L Wright, email: hlwright@liverpool.ac.uk

Keywords: neutrophils, metabolomics, PFKFB3, glycolysis, rheumatoid arthritis

1. ABSTRACT

Neutrophils are key effector leukocytes of the innate immune system and play a pivotal role in defending the host against microbial infections. Recent studies have identified a crucial link between glycolysis and neutrophil cellular functions. Using human neutrophils, we have investigated the intricate relationship between glycolysis, extracellular glucose availability, and the enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), in the regulation of reactive oxygen species (ROS) and neutrophil extracellular trap (NET) production. We have identified that PFKFB3 activity is a key regulator of neutrophil ROS and NET production, cytotoxic molecules which are both implicated in the pathogenesis of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA). Targeted inhibition of PFKFB3 expression blocked the production of ROS and NETs in a dose-dependent manner in both RA and HC neutrophils ($p < 0.01$). RA neutrophils were more sensitive to lower concentrations of PFKFB3 inhibition. We also demonstrated that RA neutrophils retain ROS and NET production in culture conditions which mimic the low glucose environments encountered in the RA synovial joint. By dissecting the intricate interplay between PFKFB3, glycolysis, and neutrophil effector functions, this study advances the understanding of the molecular mechanisms governing innate immune responses and identifies PFKFB3 as a potential therapeutic target for conditions characterized by dysregulated neutrophil activity.

2. INTRODUCTION

Complex changes in leukocyte metabolism are associated with the generation of small molecule metabolites, such as ATP, NADPH, nucleotides, and amino acids, which are required rapidly and in high abundance for cell activation, migration and differentiation [1]. Understanding the complex metabolic networks and adaptations has become more relevant since the discovery of the impact of metabolism on immunity (immunometabolism) and the realisation that cellular metabolism does much more than simply provide energy or biomass. Metabolite and metabolic fluxes can modulate activation or inhibition of cell signalling pathways and post translational modifications (PTMs) to proteins [2].

Dysregulation of immunometabolic control has been described in inflammatory diseases including rheumatoid arthritis (RA), where changes in T-cell glycolytic activity drives differentiation, hyperproliferation and hyper-migration of T-cell subsets [3-5]. RA macrophages have a disease specific metabolic signature which enables CD4⁺ T cells to differentiate into hyperproliferative pro-inflammatory helper T cells invading tissue and eliciting aggressive tissue inflammation in the synovium through immunogenic cell death [6]. The loss of self-tolerance in people with RA precedes joint inflammation by decades and is firmly engraved in the metabolic dysregulation of both the innate and adaptive immune systems [7].

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Neutrophils are the most abundant leukocyte in humans and are specialist cells of the innate immune system that play a major role in host defence against micro-organisms through phagocytosis and generation of ROS [8, 9]. Neutrophils have enormous potential to cause damage to local tissues when dysregulated and are key mediators in the pathology of RA [10]. Neutrophil survival is enhanced in inflammatory conditions by hypoxia-driven metabolic re-programming [11] and by nutrient availability at the site of inflammation [12]. Neutrophils rely on glycolysis to fuel their energy requirements, where glucose is converted into pyruvate in the cytosol for relatively low-level production of ATP and NADH [13]. The resulting pyruvate is not oxidised in the mitochondria through the TCA cycle, rather it is converted to lactate enabling the generation of NAD⁺ for re-use in the glycolytic pathway. Furthermore, inflammatory neutrophils have been shown to contain glycogen, with early evidence that neutrophil glycogen stores can be modified between circulating and tissue-recruited cells, by activation of the oxygen sensing response, and by stimulation with proinflammatory mediators [14, 15]. The first intermediate of glycolysis, glucose 6-phosphate (G6P), also fuels the pentose phosphate pathway (PPP) producing NADPH which is required to activate the NADPH oxidase (NOX2) leading to ROS production, chromatin decondensation, NOX2-dependent NET formation and NET release [16, 17].

Compared to other immune cells, the study of neutrophil immunometabolism is still in the early discovery phase. We recently measured the neutrophil metabolome in RA using ¹H NMR metabolomics and identified that levels of intracellular glucose, lactate and NADP⁺ are different in RA neutrophils compared to healthy controls [18]. The reliance on glycolysis for cellular activation is a challenge for neutrophils as sites of inflammation such as the RA synovial joint are frequently characterised by limited nutrient availability, including glucose, as well as hypoxia [19]. The aim of this work was to further investigate the metabolic pathways regulating neutrophil function in RA and healthy controls, and in particular to examine the pathways of central carbon metabolism i.e. glycolysis, glycogenolysis, gluconeogenesis and glutaminolysis to determine the importance of these in pathogenic neutrophil release of ROS and NETs in RA.

3. METHODS

3.1 Isolation and incubation of neutrophils

Ultrapure neutrophils (>99.9% purity) were isolated using the untouched neutrophil isolation kit (Stem Cell). After the blood was incubated 1:5 ratio with Hetasep (Stem Cell) for 30 min at 37 °C the nucleated cells were collected and resuspended 1:1 with ice cold isolation buffer (PBS containing 2% BSA and 0.2 mM EDTA). The suspension was then centrifuged at 400g for 5 minutes and pellet resuspended in 2mL of isolation buffer. 25µL of the antibody cocktail was added to the cell suspension and then incubated for 10 minutes on ice before adding 50µL of magnetic beads and further incubation for 10 minutes on an EasySep magnet. Cells were then collected and resuspended in RPMI media (+ L-glutamine, -HEPES, -phenol red) containing either no glucose or glucose (11mM) at 5x10⁶/mL. In some experiments, neutrophils were pre-treated with metabolic inhibitors 3PO, BPTES, MB05032 or CP-91149 at a range of concentrations (10–50µM) or 2-DG (50mM) for 15 minutes prior to activation with PMA (concentrations below).

3.2 Detection of ROS Production By Luminol-Enhanced Chemiluminescence

Following incubation, 2x10⁵ cells were resuspended in 200µL HBSS along with 1µL luminol (final concentration 10µM). The respiratory burst was stimulated with PMA (100ng/mL) and measured in a Fluostar plate reader luminometer at 37 °C.

3.3 Measurement of NET Production with Sytox Green

To determine the formation of NETs, 10⁵ neutrophils were seeded in a black 96-well plate containing Sytox green reagent (5µM) and treated firstly with or without cell signalling inhibitors for 15 min in a

humidified incubator at 37 °C. Then neutrophils were stimulated with PMA (600nM) and incubated for 4 h at 37 °C before fluorescence was measured by Fluostar plate reader at excitation 488nm and emission in the 530/30 filter.

3.4 Imaging of neutrophils on cover slips

Neutrophils were seeded (at 2×10^5 cells/500 μ L) in RPMI media in a 24-well plate containing poly-L-lysine coated coverslips, as previously described [20]. Cells were pre-treated with 3PO (50 μ M) and allowed to settle and adhere for 30 min prior to stimulation with PMA (600nM). Cells were incubated for a further 4h to allow for NET production. Cells adhered to coverslips were fixed with 4% paraformaldehyde prior to immunofluorescent staining. Briefly, coverslips were removed from the plate and washed with PBS, permeabilised with 0.05% Tween 20 in TBS, fixed with TBS (2% BSA) and then stained for 30 min on drops of TBS (2% BSA) on parafilm stretched across a clean 24-well plate. Primary antibodies used were mouse anti-myeloperoxidase (1:1000, Abcam) and rabbit anti-elastase (1:200, Abcam). Coverslips were washed three times with TBS prior to secondary antibody staining (anti-rabbit AlexaFluor488 and anti-mouse AlexaFluor647, 1:2000, Life Technologies) in TBS (+2% BSA) for 30 min. Coverslips were washed prior to staining with DAPI (1 μ g/mL). Slides were imaged on an Zeiss LSM800 microscope (Zeiss) using a 20X objective.

3.5 Measurement of Glycogen content

Neutrophil glycogen content was quantified using the Merck glycogen assay kit. Briefly, 10^6 neutrophils were lysed in 200 μ L ice-cold H₂O and boiled for 10 min at 95 °C. Lysates were centrifuged at 18,000 g at 4 °C for 10 min to remove cell debris and snap frozen in liquid nitrogen and stored at -80 °C. On the day of the measurement, 50 μ L of defrosted cell lysate was transferred to 96 well black plate and 1 μ L of hydrolysis enzyme mix was added and the plate incubated for 30 min at room temperature. To remove the effect of background glucose, a sample blank was set up for each reaction by omitting the hydrolysis enzyme mix. The sample blank was then subtracted from the sample readings. After incubation, 48 μ L of development buffer was added to the well, with 1 μ L of development enzyme mix and 1 μ L of fluorescent peroxidase substrate. The plate was incubated for 30 min at room temperature and protected from light. Fluorometric measurement was carried out with Fluostar plate reader with an excitation of 535 nm and emission of 587 nm. The final concentration of glycogen in the samples was calculated from the standard curve as per manufacturer's instructions.

3.6 Measurement of OCR with Seahorse

Oxygen consumption rate (OCR) was measured using the Seahorse XFe96 Analyser (Agilent Technologies). We seeded 2.5×10^5 neutrophils per well of a XFe96 cell culture microplates (Agilent Technologies) pre-coated with Cell-Tak. RPMI medium was supplemented with 2mM glutamine, 10mM glucose, 1mM pyruvate (All from Agilent Technologies). Plates were incubated for 30 min at 37°C and loaded into the Seahorse XFe96 Analyser. OCR was quantified at the beginning of the assay and after the sequential injection of oligomycin (2 μ M), Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazine (FCCP, 0.5 μ M) and rotenone plus antimycin A (0.5 μ M) (MitoStress Test kit, Agilent Technologies). PMA (600nM) was injected after 15 min to stimulate the oxidative burst which was quantified by calculating the area under the curve.

3.7 Measurement of Apoptosis By Flow Cytometry

Following incubation with or without inhibitors for up to 24h, 5×10^4 neutrophils were removed from culture and diluted with 200 μ L HBSS containing 0.5 μ L Annexin V-488, and incubated at room temperature in the dark for 15 min. The total volume was then made up to 250 μ L with HBSS, and 0.25 μ L propidium-iodide added (1 μ g/mL) before reading on a EasyCyte Guava flow cytometer. 5,000 events per sample were analysed.

3.8 Measurement of GLUT3 by flow cytometry

Neutrophils (5×10^4) were labelled with saturating concentrations of FITC-labelled anti-GLUT3 antibody or isotype control (BD Biosciences). Unlabelled cells were also prepared as a control. Cells were incubated in PBS (0.2% BSA) with or without antibodies for 30 minutes at 4°C. Cells were washed in PBS (BSA) and then fixed using 4% paraformaldehyde. Cells were washed again to remove excess paraformaldehyde, and then resuspended in 200µL PBS. Cell surface antibodies were detected using a Cytoflex Beckman Coulter 2.0 flow cytometer, with 10,000 cells counted per sample.

3.9 Gene expression analysis

In-house RNAseq datasets were analysed by EdgeR [21] to detect genes significantly different between RA (n=60) and HC (n=19) (adj. p-value < 0.05). Gene ontology analysis was carried out on genes with a 1.5 fold change in gene expression between RA and HC neutrophils using clusterProfiler [22, 23] and enrichPlot [24] working in R v 3.6.

3.10 NMR Metabolomics

Neutrophils were prepared for metabolite extraction as previously described [18]. Briefly, cells were centrifuged at 1000g at 25°C for 2 min, pellet was washed with ice cold PBS then centrifuged at 1000g at 25°C for 2 min. The supernatant was discarded, pellets were heated at 100°C for 1 min, and then snap-frozen in liquid nitrogen and stored at -80°C. Metabolites were extracted by addition of 50:50 v/v ice cold HPLC grade acetonitrile:water at 500µL per cell pellet, followed by a 10 min incubation on ice. Samples were sonicated three times for 30 s at 23 kHz and 10µm amplitude using an exponential probe, with 30 s rest between sonications in an ice water bath. Sonicated samples were centrifuged at 12,000g for 5 min at 4°C and the supernatant transferred to cryovials, flash frozen in liquid N₂ and lyophilised. Each lyophilised sample was resuspended in 200µL of 100µM deuterated sodium phosphate buffer pH 7.4, with 100µM trimethylsilyl propionate (TSP) and 0.05% NaN₃. Each sample was vortexed for 20 s and centrifuged at 12,000g for 1 min at 20°C. Then 180µL of each cell extract sample was transferred to 3 mm (outer diameter) NMR tubes for acquisition.

The samples were analysed using a 700 MHz NMR Avance IIIHD Bruker NMR spectrometer equipped with a TCI cryoprobe. Samples were referenced to trimethylsilylpropanoic acid (TSP) at 0 ppm. Spectra were acquired at 25°C using the 1D Carr–Purcell–Meiboom–Gill (CPMG) edited pulse sequence technique with 512 scans. Spectra were assessed to conform to minimum quality criteria as outlined by the Metabolomics Society [25] to ensure consistent linewidths, baseline corrections and water suppression. All spectra passing quality criteria were then divided into “bins” that were defined globally by the peak limits using Chenomx NMR Suite 7.1 (Chenomx Inc., Edmonton, Alberta, Canada)[26]. All peaks, both annotated in Chenomx (via manual analyses in TopSpin and Chenomx software) and unknown, were included in the bin table. A correlation-based scoring (CRS) method was applied to the data which aimed to address the problem of selecting appropriate representative bins from feature extraction in multivariate analysis [27].

3.11 Preparation of immune complexes

Insoluble immune complexes (IIC) were prepared by incubating human serum albumin with anti-human serum albumin antibody in PBS for 1h as previously described [28]. Immune complexes were washed 3 times by centrifugation at 1,000g and re-suspension in PBS before use to remove soluble immune complexes. In some experiments neutrophils were pre-treated with 3PO (0-50µM) for 15 min prior to stimulation with 10% (v/v) IIC to stimulate NET production.

3.12 Statistical analysis

Statistical analyses were performed using R v4.0.2. Univariate analysis was carried out by ANOVA when comparing more than 2 groups or Student’s t-test with application of a False-Discovery Rate (FDR) and adjusted p-value of 0.05.

4. RESULTS

4.1 Increased expression of genes regulating central carbon metabolism in RA neutrophils

In our previous study we identified that the metabolome in RA neutrophils is different from HC, mainly driven by metabolites of central carbon metabolism (glucose, ATP, NADP, lactate) [18]. In this study we wanted to further investigate the reasons for this, and therefore we first analysed the expression of genes regulating glycolysis in RA neutrophils. Using in-house RNAseq data, we identified gene ontology pathways significantly enriched in RA neutrophils. This identified altered metabolic pathways in RA neutrophils, including 'response to nutrient levels' and 'cellular response to glucose starvation' as well as neutrophil effector functions including 'positive regulation of cytokine production', 'regulation of cell-cell adhesion', 'response to oxidative stress', 'regulation of apoptotic signalling pathway' and 'response to reactive oxygen species' (Figure 1A). We next investigated the expression of specific genes involved in glycolysis in RA and HC neutrophils. Gene set lists were obtained from gene ontology dataset Panther [29]. A total 10 out of 20 genes relating to 'glycolytic process' (GO:0006096) and 'glycolytic process through fructose-6-phosphate' (GO:0061615) were significantly different between HC and RA neutrophils (Table 1, adj. p-value<0.05). A total of 6 genes had an adj. P-value <0.001 with 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) being the most increased in RA (adj. P-value = 3.39×10^{-7} , Figure 1C). The other related genes 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 2 (PFKFB2) (adj. P-value = 0.0013) and 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4) (adj. P-value = 2.15×10^{-5}), that together form the isoenzyme of Phosphofructokinase-2 (PFK2), were also significantly different (Figure 1B). Phosphoglycerate Kinase 1 (PGK1) (adj. P-value = 7.43×10^{-6}) was also increased in RA compared to control HC. Neutrophil transcriptomics analysis also highlighted an increase in gene expression for the glucose transporter gene SLC2A3 which codes for the GLUT3 protein (Figure 1C, adj. P-value = 1.22×10^{-8}). Increased plasma membrane expression of GLUT3 on RA neutrophils was confirmed by flow cytometry (Figure 1D).

Table 1. EdgeR analysis of RA and HC RNAseq data

geneID	logFC	P.Value	adj.P.Val
PFKFB3	1.89787294	1.29E-08	3.39E-07
PGK1	0.55263185	8.08E-07	7.43E-06
PFKFB4	-0.3870096	3.05E-06	2.15E-05
PFKFB2	0.69327738	0.00045022	0.00135963
BPGM	0.3152788	0.00071153	0.00202023
ALDOA	-0.2795292	0.00082148	0.00228647
PFKL	-0.3533797	0.00169033	0.00427286
PGAM2	-0.279651	0.00418266	0.00935035
HK2	0.29731291	0.01716014	0.0320336
PGAM4	-0.2748564	0.02213319	0.04010459
GPI	-0.4693708	0.03678325	0.06195483
TIGAR	0.20524246	0.04869884	0.07885046
ALDOC	-0.1957927	0.14352664	0.20009413
ENO1	0.18578163	0.14729919	0.20477002
HK3	0.18445053	0.19370564	0.25851508
GAPDH	0.09173192	0.41538745	0.49306909
PGAM1	-0.047352	0.54226617	0.61388623
HK1	0.03144933	0.69091349	0.74864493
PKM	-0.0670149	0.6521508	0.71364059
TPI1	-0.0177686	0.84185308	0.87586873




Figure 1. Dysregulation of metabolic gene expression in RA neutrophils. (A) Gene ontology analysis of genes expressed >1.5 fold higher in RA compared to HC. (B) Boxplots showing expression levels of PFKFB2, PFKFB3, PFKFB4, PGK1 in RA and HC neutrophils (***FDR<0.001, ****FDR<0.0001). (C) Gene expression of SLC2A3 in HC and RA neutrophils and (D) GLUT3 protein on the surface of HC and RA neutrophils.

4.2 Absence of extracellular glucose does not change ROS or NETs in RA neutrophils, but inhibition of glycolysis blocks ROS and NET production in both HC and RA neutrophils

In order to investigate the requirement for glycolysis to fuel ROS and NET production we incubated HC and RA neutrophils in glucose rich or glucose depleted media in the presence of PMA and measured ROS continuously by luminol-enhanced chemiluminescence. The absence or presence of glucose in the media did not affect neutrophil ROS production (Figure 2A) but did decrease NET production in HC samples (Figure 2B, $p < 0.01$). RA neutrophil NETs were not affected by the absence of extracellular glucose. Inhibition of glycolysis at the first step (hexokinase) using 2-DG significantly decreased ROS irrespective of glucose availability in both HC and in RA neutrophils (Figure 2C, p -value<0.01). 2-DG also completely inhibited NET production in glucose rich or depleted media in both HC and RA neutrophils (Figure 2D, p -value<0.01).

We next used the Seahorse XF assay to determine the changes in oxygen consumption rate (OCR) induced by either inhibition of glycolysis (by 2-DG) or the absence of glucose in the media, with and without PMA stimulation. Non-activated (untreated) neutrophils did not show any change in OCR in response to oligomycin (ATP synthase complex V inhibitor), FCCP (uncoupler of mitochondrial oxidative phosphorylation) or Rotenone and Antimycin (Rot/AA, complex I and III inhibitors) showing that resting neutrophils do not use mitochondrial respiration (Figure 2E). PMA activation on the other hand stimulated an increase in OCR by neutrophils. However after a second injection of oligomycin, no decrease in OCR was observed after the initial OCR spike. PMA-activated neutrophils were unaffected by FCCP or Rot/AA again showing that activated neutrophils do not utilise mitochondrial respiration, and indicating that the increase in OCR detected was from ROS production. When neutrophils were incubated in glucose depleted media, PMA-activated neutrophils still consumed oxygen, however to a lower rate than in glucose rich media. Injection of glucose into the media after 30 min augmented OCR. Injection of the hexokinase inhibitor 2-DG completely decreased OCR by activated neutrophils highlighting the over-reliance of upper glycolysis in NOX2-dependent ROS production (Figure 2F).




Figure 2. Effect of glucose availability on ROS and NET production. ROS and NET release in response to PMA in (A,C) glucose or (B,D) no glucose media in the absence (A,B) or presence (C,D) of the hexokinase inhibitor 2DG (* $p < 0.05$, ** $p < 0.01$). (E) Seahorse XF OCR trace of HC neutrophils incubated in glucose or no glucose media. Neutrophils were activated by injection of PMA (600nM) after 15 min as indicated. Neutrophils in glucose media were challenged with mitochondrial inhibitors: oligomycin (2 μ M), FCCP (0.5 μ M), and antimycin A plus rotenone (Rot/AA, 0.5 μ M) at timepoints indicated by arrows, whereas neutrophils in no glucose media were injected with glucose (11mM), oligomycin (2 μ M) and 2-DG (50 μ M) at timepoints indicated by arrows (n = 2 biological replicates, n = 5 technical replicates). (F) Seahorse XF OCR trace of HC and RA neutrophils incubated in glucose rich or deprived media. Neutrophils were activated with PMA after 15 min as indicated by an arrow and 2-DG was injected where indicated. Neutrophils in glucose deprived media were given glucose as indicated.

4.3 Glycogen is stored by neutrophils in low glucose environments

Glucose may be stored by cells in the form of glycogen, a multi-branched polysaccharide of glucose molecules. Glucose-1-phosphate is cleaved from the end of a glycogen chain through the action of glycogen phosphorylase and can enter glycolysis following conversion to glucose-6-phosphate. The glycogen content in HC and RA neutrophils was therefore measured at 0h and after incubation for 1h in glucose rich or depleted media. This identified an increase in glycogen stores when glucose was absent in the media in both HC and RA neutrophils. However only HC neutrophils reached significance (Figure 3A, p -value < 0.05). Intracellular glycogen production in glucose depleted media was inhibited when neutrophils were treated with the hexokinase inhibitor 2-DG (Figure 3A, p -value < 0.05). To determine whether glycogen is utilised by neutrophils to provide the glucose needed to fuel ROS and NET production by the Pentose Phosphate Pathway (PPP), neutrophil activation was tested in the absence and presence of CP-91149 (0–50 μ M), a selective inhibitor of glycogen phosphorylase. No significant difference in ROS or NET production was observed in the presence of CP-91149 in HC and RA neutrophils incubated in glucose rich or glucose depleted media. (Figure 3B,C).




Figure 3. Effect of extracellular glucose on glycogen stores in HC and RA neutrophils. (A) Measurement of intracellular glycogen content of neutrophils incubated in glucose or no glucose depleted media and treated with or without an inhibitor of hexokinase 2-DG for 1h. (* $p < 0.05$.) (B) Effect of inhibiting glycogenolysis on neutrophil (B) ROS and (C) NET production by neutrophils incubated in glucose or no glucose media and treated with increasing concentrations of inhibitor of glycogenolysis CP-91149 (0 – 50 μ M).

4.4 PFKFB3 is a key regulator of central glycolysis, regulating ROS and NET production by RA and HC neutrophils

Fructose-2,6-phosphate (PFK-2) is a key enzyme in upper glycolysis, and our gene expression analysis identified the PFK-2 subunit PFKFB3 as being significantly increased in RA neutrophils (Figure 1B). We therefore inhibited PFK-2 activity by 3PO, a chemical inhibitor of the PFKFB3 subunit. ROS production was inhibited in a dose dependent manner (0-50 μ M) in both HC and RA neutrophils (Figure 4A, $P < 0.01$). In HC and RA neutrophils, increasing concentrations of 3PO significantly decreased ROS production in glucose rich and glucose depleted media. In glucose rich and glucose depleted media, RA neutrophil NET production was significantly inhibited at all concentrations from 10 μ M to 50 μ M ($p < 0.001$). In HC neutrophils, 3PO did not inhibit NETs at a concentration of 10 μ M, and a significant decrease was only observed at 25 μ M and 50 μ M (Figure 4B,C $p < 0.01$) indicating RA neutrophils may be more sensitive to PFKFB3 inhibition. This was confirmed by immunofluorescent staining of NETs on coverslips after 4h incubation with PMA in the absence or presence of 3PO (50 μ M) (Figure 4C). Finally we also determined that 3PO was able to significantly inhibit NET production in response to IIC which mimic auto-antibody immune complexes such as rheumatoid factor, commonly found in the blood serum and synovial fluid of people with RA (Figure 4D, $p < 0.01$).




Figure 4. Inhibition of PFKFB3 in neutrophils using 3PO. (A) ROS (B) and NET production in response to PMA by neutrophils incubated with 3PO (0 – 50 μ M) in glucose or no glucose media (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). (C) Representative images of HC and RA NETs produced in response to PMA in the absence or presence of 3PO (50 μ M). Blue = DNA, DAPI; Red = MPO; Green = elastase. (D) NET production in response to insoluble immune complexes incubated with 3PO (0 – 50 μ M, ** $p < 0.01$).

Next we determined the effect of 3PO on neutrophil apoptosis by incubating RA and HC neutrophils for 24h in the absence and presence of 3PO. Interestingly, in both glucose rich and glucose depleted

media we observed no difference in the overall percentage of live (annexin V negative, PI negative) neutrophils. However the populations of early (annexin V positive, PI negative) and late apoptotic (annexin V positive, PI positive) were significantly decreased and increased respectively in both RA and HC neutrophils ($p < 0.05$) by 3PO (Figure 5A).




Figure 5. Effect of PFKFB3 inhibition with 3PO on neutrophil apoptosis. (A) Percentage of late apoptosis (red), early apoptosis (yellow) or live (green) HC and RA neutrophils incubated in glucose or no glucose media and treated for 24 h with varying concentrations of 3PO (0 – 50 μM). (B) Representative flow cytometry traces for HC neutrophils showing annexin V and PI positive/negative gating.

Finally we performed preliminary NMR metabolomics analysis on neutrophils incubated for 4h in the absence or presence of 3PO (50 μM) in glucose rich or glucose depleted media. The absence of glucose in the media decreased the intracellular levels of the glucose metabolite in both HC and RA neutrophils and also decreased the levels of lactic acid compared to neutrophils incubated in glucose rich media (Figure 6A). The presence of 3PO increased the intracellular levels of glutamine and phenylalanine and decreased glutathione in both HC and RA neutrophils in glucose rich and glucose depleted media (Figure 6B). Further experiments will be performed to confirm the initial findings.




Figure 6. ^1H NMR analysis of RA and HC neutrophils with PFKFB3 inhibition by 3PO. Boxplots of metabolites measured by ^1H -NMR from neutrophils incubated in glucose or no glucose media for 4h with and without treatment with 50 μM 3PO. (A) The intracellular levels of glucose and lactic acid and (B) glutamine, phenylalanine and glutathione were affected by both glucose depletion and PFKFB3 inhibition by 3PO.

4.5 Inhibitors of gluconeogenesis and glutaminolysis do not affect ROS and NET production in RA and HC neutrophils

Finally we investigated the effect of inhibiting gluconeogenesis and glutaminolysis on ROS and NET production by RA and HC neutrophils. MB05032 is a potent FBPase (FBP1) inhibitor which inhibits gluconeogenesis and BPTES inhibits glutaminase-1. MB05032 inhibited HC NETs at the highest concentration tested (50 μ M, $p < 0.05$) but otherwise neither inhibitor significantly inhibited ROS or NET production in RA or HC neutrophils in glucose rich or glucose depleted media (Figure 7).




Figure 7. Effect of glutaminolysis and gluconeogenesis on neutrophil activation. (A) ROS (B) and NET production in response to PMA by RA and HC neutrophils in glucose or no glucose media when treated with an inhibitor of gluconeogenesis MB05032 or an inhibitor of glutaminolysis BPTES (0 – 50 mM) (* $p < 0.05$).

6. DISCUSSION

In this study we investigated HC and RA neutrophil responses when challenged with inhibitors of central carbon metabolism or low extracellular glucose concentrations. Recent studies have highlighted the importance of pathways connected to glycolysis in neutrophils, including glycogenolysis, gluconeogenesis, glutaminolysis and PPP [17, 18] and this work provides new information about the critical role of glucose metabolism in human neutrophils.

Neutrophils are the first responders to inflamed sites. These environments generally have lower glucose concentrations than peripheral blood, a potentially unfavourable environment for neutrophils given their reliance on glycolysis for energy production and activation [16]. However, neutrophils are often found at high concentrations in low glucose, inflamed sites, for example in synovial fluid from people with RA [19]. Our first experiments confirmed the reports of others [30-32] that mitochondrial respiration is not required for energy production or an oxidative burst in HC or RA neutrophils. This notion was recently challenged by a study which suggested that glucose restricted tumour microenvironment induces immature murine, c-Kit⁺ neutrophils subsets which maintain local immune suppression by using mitochondrial fatty acid oxidation to support NADPH oxidase-dependent ROS production [31], further highlighting the important differences between human and murine

neutrophils [33]. Using the Seahorse XFe96 XF analyser we showed that when HC and RA neutrophils were challenged with inhibitors or stimulators of mitochondrial respiration there was no change in OCR. This demonstrates that mitochondria do not participate in energy production for neutrophil function via oxidative phosphorylation which reinforces the notion that glycolysis is the only pathway utilised by blood neutrophils for the production of ATP.

We explored neutrophil ROS production using a combination of luminol-enhanced chemiluminescence and the Seahorse XFe96 XF analyser. The luminol-enhanced chemiluminescence assay is relatively simple to use and is a high sensitivity and cost effective method to detect ROS production and measures both extracellular and intracellular ROS [34]. ROS production measured by Seahorse XFe96 XF provides a direct, non-invasive, real-time detection and quantification of neutrophil activation by measuring oxygen consumption rate (OCR). We confirmed that neutrophils do require glycolysis for ROS and NET production, given the complete inhibition of both in HC and RA neutrophils by 2-DG as previously reported. However, the absence of glucose in the extracellular media did not completely inhibit ROS production. Indeed, we detected decreased OCR of activated neutrophils when measured by Seahorse compared to neutrophils in glucose rich media. However, no decrease was observed when neutrophil ROS was measured by luminol-enhanced chemiluminescence in depleted media. These diverging results could be attributed to the mode of ROS detection by the two different assays. The Seahorse OCR assay measures depletion of $^2\text{O}_2$ via the activity of the NOX2 NADPH oxidase. This is the first step in ROS production. During the respiratory burst, NOX2 reduces superoxide ($^2\text{O}_2$) to $^2\text{O}_2^-$, which is then converted to hydrogen peroxide (H_2O_2) by superoxide dismutase. H_2O_2 may then react with MPO to form hypochlorous acid (HOCl) and other secondary oxidants [8]. Luminol detects both extracellular and intracellular ROS production by NOX2 and MPO.

NET formation is dependent on ROS production and inhibition of intragranular MPO activity has been shown to correlate with inhibition of NET formation [34-36]. When measuring NET formation at a single timepoint of 4h, no differences were observed between glucose rich and glucose depleted media. However complete inhibition of glycolysis by 2-DG prevented NET formation. This could highlight that intracellular ROS formation, irrespective of the extracellular glucose environment, is sufficient for processing by MPO in order to trigger NET formation.

Glycogen stores may be broken down to increase intracellular glucose levels, and as previously shown glycogen is essential for inflammatory neutrophil function [12]. Neutrophils have been observed to accumulate glycogen as neutrophils change from circulating to elicited peritoneal cells in guinea pigs [15]. A more recent study observed an increase in glycogen granules during inflammation in neutrophils from people with sepsis [37], and the authors suggested the morphological evaluation of the cells could be used as a useful biomarker for rapid and economical diagnosis of sepsis. The increase in glycogen stores has also been studied in COVID-19 patients where neutrophils have been found to have an increased amount of stored glycogen compared to healthy controls [38]. In our experiments we observed a significant increase in glycogen storage when both HC and RA neutrophils were incubated in glucose depleted media for 1h, which highlights a metabolic adaptation to the extracellular environment. Inhibition of glucose breakdown by 2-DG completely stopped glycogen formation in glucose depleted media. This is because the first step in glycogen formation requires the transformation of glucose to glucose-6-phosphate by hexokinase, a reaction that is inhibited by 2-DG. When ROS production was measured in the presence of the inhibitor of glycogenolysis, CP-91449, no significant change was reported in ROS or NET production by HC or RA neutrophils in the presence of CP-91449.

Our transcriptomics data provided an extra layer of insight into the dysregulation of metabolic pathways in RA neutrophils. Functional enrichment analysis identified glycolytic processes as being upregulated in RA neutrophils, with the most significantly altered genes in RA being PFKFB2 and

PFKFB3. Four different PFK-2/FBPase-2 isozymes have been identified and the overexpression of two isozymes (PFKFB3 and PFKFB4) has been demonstrated in various solid tumours and haematological cancer cells [39]. Peripheral and tissue resident T-cells from people with RA have a unique metabolic signature with an impairment of glycolysis due to a deficiency of PFKFB3, resulting in delayed glycolysis and increased PPP via the up-regulation of glucose-6-phosphate dehydrogenase (G6PD) [3]. The ratio of these two enzymes in T cells correlates to disease activity in people with RA which suggests a dysregulation of pro-inflammatory properties of T cells directly affected by PFKFB3 and G6PD [4, 40]. T cells are therefore diverting glucose from energy generation towards synthesis of biomass precursors with functional consequences that include hyper-proliferation, G2/M bypass and deviated functional commitment [41].

Little is known about the role of PFKFB3 in regulating neutrophil metabolism and function. For this reason we tested whether neutrophils were still able to activate the NOX2 pathway to produce ROS and NETs when challenged with the PFKFB3 inhibitor 3PO. We observed a concentration dependent inhibition of ROS production by 3PO in HC and RA neutrophils in both glucose rich and depleted media. NET production was also inhibited by 3PO, although RA neutrophils were more sensitive to 3PO inhibition at lower concentrations than HC neutrophils. Measurement of neutrophil apoptosis after 24h incubation showed that increasing concentrations of 3PO increased the number of late apoptotic cells and decreased the early apoptotic cell count, without significantly altering the overall proportions of live/apoptotic cells. Enhancement of PFKFB3 transcription and translation facilitates the production of neutrophil inflammatory factors has been identified during the acute phase of sepsis [42]. Pharmacological inhibition or depletion of PFK-2 by small interfering RNA (siRNA) leads to a significant decrease in NOX2 activity response to various neutrophil stimuli [43]. Among the four isoenzymes of PFK-2, PFKFB3 and PFKFB4 are the two main isoenzymes overexpressed in various human cancers and in neutrophils. PFKFB3 is a critical glycolysis regulatory enzyme that promotes fructose 2,6-bisphosphate (F2,6BP) production which in turn activates PFK-1, increasing glycolytic output. It has the highest kinase:phosphatase activity ratio of all the PFKFB isoforms [44], proving a possible explanation as to why inhibition of this isoform has such a marked effect on cellular function. In vitro experiments showed glycolytic metabolism with PFKFB3 involvement supports inflammatory cytokine expression [42]. Furthermore, a significant increase has been observed in the expression of PFKFB3 in LPS-challenged and sepsis neutrophils compared to controls [45]. PFKFB4 was found to be associated with immune cell infiltration and immunological checkpoints in non-small cell lung cancer [46]. In neutrophils, selectively targeting phosphofructokinase-1 liver type (PFKL) highlighted how this protein suppresses the NOX2-dependent oxidative burst [47]. It was also observed that PMA, LPS, or cholesterol crystals reduced PFKL activity to promote NOX2-dependent NETosis, except when the cells were treated with PFKL agonists NA-11 or LDC7559. In contrast, NETosis induced in a NOX2-independent manner by the ionophore nigericin did not change PFKL activity and was not blocked by NA-11 [47]. PFKL knockdown in macrophages was also shown to reduce glycolytic flux as evidenced by diminished lactate and resulted in diversion of glucose into the PPP [48]. However little else is known about the role of this enzyme in neutrophils. Our NMR analysis highlights an increase in mitochondrial metabolites glutamine and phenylalanine with a decrease in antioxidant metabolite glutathione when neutrophils are treated with 3PO. This intracellular metabolite switch could point to alternative metabolic pathways adopted by neutrophils to overcome targeted inhibition and prolong inflammation.

One of the limitations of our study was that the participants with RA were receiving one or more disease-modifying anti-rheumatic drugs (DMARDs e.g. methotrexate and hydroxychloroquine), and this may account for some of the heterogeneity in the results for the RA group. Several DMARDs have known effects on neutrophil functions, including decreasing ROS production and degranulation [9]. We saw wider experimental variation in the RA samples, which could be explained by the effect of DMARDs, differences in donor disease activity (DAS28) or other clinical factors such as inflammation

(e.g. CRP). We were also unable to measure neutrophil phagocytosis or bacterial killing functions as part of these studies, and these should be the subject of future investigations. These future experiments will be essential to understand whether neutrophils could still function in host defence with the inhibition of PFKFB3, and whether this may be a suitable target for the development of future therapies.

In summary, we have shown in this study that neutrophils are metabolically adapted to maintain ROS production in low glucose environments such as sites of inflammation, and that NET production is preserved in RA neutrophils in low glucose environments. We have also identified PFKFB3 as a critical regulator of glycolytic flux in human neutrophils, and that PFKFB3 is over expressed in neutrophils from people with RA. Further experiments to determine neutrophil cytotoxic killing capacity in the presence of PFKFB3 inhibition will determine whether the metabolic enzyme PFK-2 could be a potential therapeutic target for the treatment of immune-mediated inflammatory diseases such as RA.

7. ACKNOWLEDGEMENTS

We would like to thank the rheumatology nurses and consultants at Liverpool University Hospital NHS Foundation Trust for their assistance in recruiting patients for this study. We thank Dr Amy Chadwick for use of the Seahorse XFe96 analyser. We would like to thank Prof Steven Edwards for constructive and critical discussions throughout this project.

8. ETHICAL APPROVAL

The study was approved by the University of Liverpool Central University Research Ethics Committee C and NRES Committee North West (Greater Manchester West, Manchester, UK) for respectively the isolation of neutrophils from HC and RA blood. All participants gave written, informed consent in accordance with the declaration of Helsinki. All patients fulfilled the ACR 2010 criteria for the diagnosis of RA and were Biologics naïve. People with RA were recruited from Liverpool University Hospital Foundation Trust in Liverpool, UK. Healthy controls were recruited from volunteers and colleagues at the University of Liverpool.

9. AUTHOR CONTRIBUTIONS

MFA designed the experiments, carried out the experiments, analysed the data and wrote the manuscript. GA carried out the experiments, analysed the data and revised the manuscript. AN carried out the experiments and revised the manuscript. CL carried out the experiments and revised the manuscript. MMP designed the experiments, analysed the data and wrote the manuscript. HLW designed the research, analysed the data, and wrote the manuscript.

10. FUNDING

MFA was funded by a Versus Arthritis and Masonic Charitable Fund PhD scholarship (Grant No. 22193). GA was funded by a University of Liverpool CIMA MRes scholarship and a Dunhill Medical Trust and University of Liverpool PhD Scholarship. AN was funded by a Connect Immune Research and The Lorna & Yuti Chernajovsky Biomedical Research Foundation Grant (Grant No. 22925). HLW was funded by a Versus Arthritis Career Development Fellowship (Grant No. 21430). The equipment and software licences used in the Shared Research Facility for NMR metabolomics were funded by the MRC (Grant No. MR/M009114/1).

11. DATA AVAILABILITY

All data presented in this manuscript are available upon reasonable request to the corresponding author.

12. CONFLICT OF INTEREST

The authors declare no conflicts of interest. All grant funding for the research has been declared. The authors have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years. No other relationships or activities that could appear to have influenced the submitted work.

13. REFERENCES

1. Gaber, T., C. Strehl, and F. Buttgerit, *Metabolic regulation of inflammation*. Nature Reviews Rheumatology, 2017. **13**(5): p. 267–279-267–279.
2. Voss, K., et al., *A guide to interrogating immunometabolism*. Nature Reviews Immunology, 2021. **21**(10): p. 637–652-637–652.
3. Yang, Z., et al., *Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells*. Journal of Experimental Medicine, 2013. **210**(10): p. 2119–2134-2119–2134.
4. Yang, Z., et al., *Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis*. Science Translational Medicine, 2016. **8**(331): p. 331ra38–331ra38-331ra38–331ra38.
5. Weyand, C.M. and J.J. Goronzy, *Immunometabolism in early and late stages of rheumatoid arthritis*. 2017. **13**(5): p. 291–301-291–301.
6. Weyand, C.M. and J.J. Goronzy, *Immunometabolism in the development of rheumatoid arthritis*. Immunological Reviews, 2020. **294**(1): p. 177–187-177–187.
7. Li, Y., J.J. Goronzy, and C.M. Weyand, *DNA damage, metabolism and aging in pro-inflammatory T cells*. Experimental Gerontology, 2018. **105**: p. 118–127-118–127.
8. Glennon-Alty, L., et al., *Neutrophils and redox stress in the pathogenesis of autoimmune disease*. Free Radic Biol Med, 2018. **125**: p. 25-35.
9. Wright, H.L., et al., *Neutrophil function in inflammation and inflammatory diseases*. Rheumatology (Oxford), 2010. **49**(9): p. 1618-31.
10. Wright, H.L., R.J. Moots, and S.W. Edwards, *The multifactorial role of neutrophils in rheumatoid arthritis*. Nature reviews. Rheumatology, 2014. **10**: p. 593–601-593–601.
11. Walmsley, S.R., et al., *Hypoxia-induced neutrophil survival is mediated by HIF-1 alpha-dependent NF-kappaB activity*. Journal of Experimental Medicine, 2005. **201**(1): p. 105–115-105–115.
12. Sadiku, P., et al., *Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis*. Cell Metabolism, 2021. **33**(2): p. 411–423.e4-411–423.e4.
13. Sbarra, A.J. and M.L. Karnovsky, *The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes*. The Journal of biological chemistry, 1959. **234**: p. 1355–1362-1355–1362.
14. Sadiku, P., et al., *Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses*. Journal of Clinical Investigation, 2017. **127**(9): p. 3407–3420-3407–3420.
15. Robinson, J.M., M.L. Karnovsky, and M.J. Karnovsky, *Glycogen accumulation in polymorphonuclear leukocytes, and other intracellular alterations that occur during inflammation*. Journal of Cell Biology, 1982. **95**(3): p. 933–942-933–942.
16. Azevedo, E.P., et al., *A Metabolic Shift toward Pentose Phosphate Pathway Is Necessary for Amyloid Fibril- and Phorbol 12-Myristate 13-Acetate-induced Neutrophil Extracellular Trap (NET) Formation*. Journal of Biological Chemistry, 2015. **290**(36): p. 22174–22183-22174–22183.
17. Chokesuwattanaskul, S., et al., *A robust intracellular metabolite extraction protocol for human neutrophil metabolic profiling*. PLoS One, 2018. **13**(12): p. e0209270.

18. Chokesuwattanaskul, S., et al., *Metabolic Profiling of Rheumatoid Arthritis Neutrophils Reveals Altered Energy Metabolism That Is Not Affected by JAK Inhibition*. *Metabolites*, 2022. **12**(7): p. 650-650.
19. Anderson, J.R., et al., *1H NMR Metabolomics Identifies Underlying Inflammatory Pathology in Osteoarthritis and Rheumatoid Arthritis Synovial Joints*. *Journal of Proteome Research*, 2018. **17**(11): p. 3780–3790-3780–3790.
20. Chapman, E.A., et al., *Caught in a Trap? Proteomic analysis of neutrophil extracellular traps in rheumatoid arthritis and systemic lupus erythematosus*. *Frontiers in Immunology*, 2019. doi: **10.3389/fimmu.2019.00423**.
21. Robinson, M.D., D.J. McCarthy, and G.K. Smyth, *edgeR: a Bioconductor package for differential expression analysis of digital gene expression data*. *Bioinformatics*, 2010. **26**(1): p. 139-40.
22. Wu, T., et al., *clusterProfiler 4.0: A universal enrichment tool for interpreting omics data*. *The Innovation*, 2021. **2**(3): p. 100141-100141.
23. Yu, G., et al., *clusterProfiler: an R package for comparing biological themes among gene clusters*. *OMICS*, 2012. **16**(5): p. 284-7.
24. Yu, G., *enrichplot: Visualization of Functional Enrichment Result*. 2021.
25. Sumner, L.W., et al., *Proposed minimum reporting standards for chemical analysis*. *Metabolomics*, 2007. **3**(3): p. 211–221-211–221.
26. Weljie, A.M., et al., *Targeted Profiling: Quantitative Analysis of 1H {NMR} Metabolomics Data*. *Analytical Chemistry*, 2006. **78**(13): p. 4430–4442-4430–4442.
27. Grosman, R., *Nmr metabolic profiling of mosquito species to understand insecticide resistance*. 2020.
28. Fossati, G., R.C. Bucknall, and S.W. Edwards, *Insoluble and soluble immune complexes activate neutrophils by distinct activation mechanisms: changes in functional responses induced by priming with cytokines*. *Ann Rheum Dis*, 2002. **61**(1): p. 13-9.
29. The Gene Ontology, C., *Expansion of the Gene Ontology knowledgebase and resources*. *Nucleic Acids Res*, 2017. **45**(D1): p. D331-D338.
30. Kramer, P.A., et al., *A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: Implications for their use as bioenergetic biomarkers*. *Redox Biology*, 2014. **2**: p. 206–210-206–210.
31. Rice, C.M., et al., *Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression*. *Nature Communications*, 2018. **9**(1).
32. Grudzinska, F.S., et al., *Real-time assessment of neutrophil metabolism and oxidative burst using extracellular flux analysis*. *Frontiers in Immunology*, 2023. **14**.
33. Mestas, J. and C.C. Hughes, *Of mice and not men: differences between mouse and human immunology*. *J Immunol*, 2004. **172**(5): p. 2731-8.
34. Bedouhène, S., et al., *Luminol-amplified chemiluminescence detects mainly superoxide anion produced by human neutrophils*. *American journal of blood research*, 2017. **7**: p. 41–48-41–48.
35. Metzler, K.D., et al., *Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity*. *Blood*, 2011. **117**(3): p. 953–959-953–959.
36. Björnsdóttir, H., et al., *Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species*. *Free Radical Biology and Medicine*, 2015. **89**: p. 1024–1035-1024–1035.
37. Ghosh, A., et al., *Glycogen accumulation in neutrophil can be a marker of sepsis*. *International Journal of Applied and Basic Medical Research*, 2020. **10**(1): p. 22-22.
38. Borella, R., et al., *Metabolic reprogramming shapes neutrophil functions in severe COVID-19*. *European Journal of Immunology*, 2021. **52**(3): p. 484–502-484–502.
39. Kotowski, K., et al., *Role of PFKFB3 and PFKFB4 in Cancer: Genetic Basis, Impact on Disease Development/Progression, and Potential as Therapeutic Targets*. *Cancers (Basel)*, 2021. **13**(4).

40. Weyand, C.M., Y. Shen, and J.J. Goronzy, *Redox-sensitive signaling in inflammatory T cells and in autoimmune disease*. Free Radical Biology and Medicine, 2018. **125**: p. 36–43–36–43.
41. Weyand, C.M., M. Zeisbrich, and J.J. Goronzy, *Metabolic signatures of T-cells and macrophages in rheumatoid arthritis*. Current Opinion in Immunology, 2017. **46**: p. 112–120–112–120.
42. Liu, D., et al., *Long noncoding RNA GSEC promotes neutrophil inflammatory activation by supporting PFKFB3-involved glycolytic metabolism in sepsis*. Cell Death & Disease, 2021. **12**(12).
43. Baillet, A., et al., *Unexpected function of the phagocyte NADPH oxidase in supporting hyperglycolysis in stimulated neutrophils: key role of 6-phosphofructo-2-kinase*. The FASEB Journal, 2016. **31**(2): p. 663–673–663–673.
44. Sakakibara, R., et al., *Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase*. J Biochem, 1997. **122**(1): p. 122-8.
45. Xu, J., et al., *Deficiency of Myeloid Pfkfb3 Protects Mice From Lung Edema and Cardiac Dysfunction in LPS-Induced Endotoxemia*. Frontiers in Cardiovascular Medicine, 2021. **8**.
46. Zhou, Y., et al., *Effect of PFKFB4 on the Prognosis and Immune Regulation of NSCLC and Its Mechanism*. International Journal of General Medicine, 2022. **Volume 15**: p. 6341–6353–6341–6353.
47. Amara, N., et al., *Selective activation of PFKL suppresses the phagocytic oxidative burst*. Cell, 2021. **184**(17): p. 4480–4494.e15–4480–4494.e15.
48. Graham, D.B., et al., *Functional genomics identifies negative regulatory nodes controlling phagocyte oxidative burst*. Nature Communications, 2015. **6**(1).